Fiche société
Xenon Pharmaceuticals Inc.
Traitements, essais et publications liés.
Traitements5programmes
Essais4liés
Publications3liées
SourceDBlocale
Traitements
5| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| XEN1101This study will evaluate the long term safety, tolerability, pharmacokinetics (PK), and efficacy of XEN1101 in subjects with Focal Onset Seizures (FOS) or Primary Generalized Tonic-Clonic Seizures (PGTCS) for the treatment of seizures for up to 6 years. | Épilepsie | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Bulgaria, Chile, Croatia, … | À vérifier |
| XEN1101This study will evaluate the long term safety, tolerability, pharmacokinetics (PK), and efficacy of XEN1101 in subjects with Focal Onset Seizures (FOS) or Primary Generalized Tonic-Clonic Seizures (PGTCS) for the treatment of seizures for up to 6 years. | Épilepsie | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Bulgaria, Canada, Chile, Croatia, Czechia, Finland, France, Georgia, Germany, Hungary, Ireland, Israel, Italy, Mexico, Netherlands, … | À vérifier |
| XEN1101This study will evaluate the long term safety, tolerability, pharmacokinetics (PK), and efficacy of XEN1101 in subjects with Focal Onset Seizures (FOS) or Primary Generalized Tonic-Clonic Seizures (PGTCS) for the treatment of seizures for up to 6 years. | Épilepsie | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Bulgaria, Canada, Chile, Croatia, Czechia, France, Germany, Israel, Italy, Mexico, Netherlands, Poland, Portugal, Spain, United Kingdom | À vérifier |
| XEN1101This study will evaluate the long term safety, tolerability, pharmacokinetics (PK), and efficacy of XEN1101 in subjects with Focal Onset Seizures (FOS) or Primary Generalized Tonic-Clonic Seizures (PGTCS) for the treatment of seizures for up to 6 years. | Épilepsie | Phase 3 | À vérifier | United States, Argentina, Australia, Austria, Belgium, Bulgaria, Chile, Croatia, Czechia, Finland, France, Germany, Hungary, Israel, Italy, Japan, Mexico, Netherlands, Poland, Portugal, … | À vérifier |
| XEN1101This study will evaluate the long term safety, tolerability, pharmacokinetics (PK), and efficacy of XEN1101 in subjects with Focal Onset Seizures (FOS) or Primary Generalized Tonic-Clonic Seizures (PGTCS) for the treatment of seizures for up to 6 years. | Épilepsie | Phase 2 | À vérifier | United States, Canada, Georgia, Germany, Italy, Moldova, Spain, Ukraine, United Kingdom | À vérifier |
Essais cliniques
4| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| XEN1101 | Épilepsie | Phase 2 | NCT03796962 | X-TOLE — A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy | ACTIVE_NOT_RECRUITING |
| XEN1101 | Épilepsie | Phase 3 | NCT05716100 | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) | RECRUITING |
| XEN1101 | Épilepsie | Phase 3 | NCT05667142 | X-ACKT — A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures | RECRUITING |
| XEN1101 | Épilepsie | Phase 3 | NCT05718817 | X-TOLE4 — An Open-label Study of XEN1101 in Epilepsy | ENROLLING_BY_INVITATION |
Publications
3| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| XEN1101 | Potassium Channelopathies and Precision Medicine Approaches in Epilepsy: A Systematic Review of Personalized Treatment Strategies. | Current neuropharmacology | ||
| XEN1101 | KCNQ2 Channel as a Druggable Epilepsy Target: Advances in Pharmacological Modifiers. | CNS & neurological disorders drug targets | ||
| XEN1101 | From Retigabine to Azetukalner: Reviving Voltage-Gated Potassium Channels for Epilepsy Therapy. | Archiv der Pharmazie |